What Is Preclinical Development Research for Ophthalmic Drugs

The preclinical research phase of ophthalmic drug development refers to the testing of ophthalmic products for activity and ocular toxicity in in vitro and in vivo studies before they can be tested in humans. In the preclinical stage, animal model studies of ocular diseases are combined with cellular and biochemical assays to understand the role of major ophthalmic products and provide relevant pharmacological profiles, data from acute and short-term ocular toxicity studies in at least two animals, and early dosage studies. Research tests throughout preclinical development generally include pharmacology of absorption, distribution, metabolism, and excretion (ADME), metabolic stability, pharmacokinetics, immunogenicity, and biomarkers. Data at this stage are used to determine whether human clinical trials and the starting dose guide clinical trials.

Service Overview

Early, comprehensive preclinical development services can significantly reduce costs and time. As one of the world leaders in ophthalmology, Ace Therapeutics has a dedicated research team to accelerate the development of your ophthalmology program. With our scientists' many years of research experience in ophthalmology, you have reason to believe that we are your trusted assistants to promote the research and development of your project.

Ace Therapeutics is committed to providing flexible solutions for ophthalmic drug preclinical research. This is to evaluate drugs for diabetic retinopathy, glaucoma, macular degeneration, retinitis pigmentosa, dry eye syndrome and other eye diseases. Our experienced team of experts provides a wide range of preclinical research services and expert guidance through this critical safety assessment phase, helping clients around the world avoid obstacles and expedite preclinical trials.

At Ace Therapeutics, we provide comprehensive and high-quality preclinical drug development services. Our clients benefit from our consulting expertise to expedite the entire drug development process leading to regulatory submission.

According to global customers' project research needs, Ace Therapeutics provides the following preclinical research services for ophthalmic drugs, including but not limited to:

*Note: Ace Therapeutics can provide customized services according to customer needs.

Why Choose Us?

• Preclinical consulting services throughout the ophthalmic drug development process.
• Hundreds of validated ocular disease models.
• Expert team with over 10 years' experience in the field of ocular disease research.
• Comprehensive and advanced technology platform.
• Take the user as the center and implement customized services in accordance with the principle of meeting user needs.

Ace Therapeutics is a comprehensive solution provider for ophthalmology. We are committed to providing professional and systematic ophthalmic drug preclinical research services for researchers and pharmaceutical companies around the world. Each project will be custom designed according to the client's requirements and described in a detailed report. If you are interested in our services or need more detailed information, please feel free to contact us. Our experienced scientists are ready to help you!

Reference

1. Shah M, Cabrera-Ghayouri S, Christie LA,et al. Translational Preclinical Pharmacologic Disease Models for Ophthalmic Drug Development. Pharm Res. 2019 Feb 25;36(4):58.

• Customized In Vivo Ocular Models
• Ophthalmic Drug Discovery Services
• Ocular Biomarker Services
• Therapeutic Areas in Ophthalmology

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit